enzastaurin has been researched along with Lymphoma, B-Cell in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Sacchi, S; Todoerti, K | 1 |
| Morschhauser, F; Ysebaert, L | 1 |
| Bari, A; Civallero, M; Cosenza, M; Sacchi, S | 1 |
| Bari, A; Civallero, M; Cosenza, M; Grisendi, G; Marcheselli, L; Roat, E; Sacchi, S | 1 |
| Ogura, M | 1 |
| Aster, JC; Cruz, JC; Darstein, C; de Vos, S; Enas, N; Flynn, PJ; Goldberg, SL; Kahl, BS; Kutok, JL; LaCasce, A; Laughlin, M; Musib, L; Neuberg, D; Robertson, MJ; Rowland, K; Savage, KJ; Shipp, MA; Slapak, CA; Thornton, D; Vose, JM | 1 |
1 review(s) available for enzastaurin and Lymphoma, B-Cell
| Article | Year |
|---|---|
Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies.
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Lymphoma, B-Cell; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors | 2011 |
2 trial(s) available for enzastaurin and Lymphoma, B-Cell
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunohistochemistry; Indoles; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Recurrence | 2007 |
3 other study(ies) available for enzastaurin and Lymphoma, B-Cell
| Article | Year |
|---|---|
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coculture Techniques; Drug Combinations; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, B-Cell; Oncogene Protein v-akt; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2010 |
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Indoles; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Rituximab; Thalidomide | 2011 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Humans; Indoles; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2012 |